Skip to main content

Core value dossiers for medical technologies

Essential tool to support market access and marketing efforts through the lifecycle of the product

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Health apps reimbursement process updated in Belgium

In July 2023, Belgian National Institute for Health and Disability Insurance (INAMI-RIZIV) significantly updated the process to obtain reimbursement for health apps (“application mobile médicale”) following a joint revision of the existing process with other stakeholders. 

The key changes in the process are that more stakeholders can submit an application to INAMI-RIZIV for temporary or permanent reimbursement, including industry (manufacturer or distributor companies), hospitals, and scientific/professional societies. New application forms are now available depending on the applicant and requested reimbursement (temporary or permanent). Temporary reimbursement can be provided for innovative technologies, which need to collect more evidence, for several years (typically three), with subsequent decision-making on permanent reimbursement.

The new process will come into force on October 1, 2023.

See more information in French here and in Dutch here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Contact us to get a free, three-month, no-obligation trial.